Development of Human Recombinant Antibodies Against ROR1 Tumor Antigen

Q: How can I download an article?

To download an article from SID, first log in to the site, search for the article title, and click on the 'Download Article' option.

Q: How can I download an ISI article?

To download an ISI article on SID, enter the keyword or article title in the search bar, view the relevant results, click on the desired article, and select the 'Download Article' option.

Q: How can I access the SID database?

To access the SID database, visit SID.ir, create an account, and log in to access scientific resources.

Q: Is downloading articles from SID free?

Some articles on SID are available for free, while others require payment. Details are specified on the article's page.

Bemani Peyman; Moazen Setareh; NADIMI ELHAM; NEJATOLLAHI FOROOGH

مرکز اطلاعات علمی Scientific Information Database (SID) - Trusted Source for Research and Academic Resources

Journal Paper

Paper Information

Journal: REPORTS OF BIOCHEMISTRY AND MOLECULAR BIOLOGY Year:2022 | Volume:11 | Issue:2 Page(s): 282-288

Download Full-Text

View:

Download:

Cites:

Information Journal Paper

Title

Development of Human Recombinant Antibodies Against ROR1 Tumor Antigen

Author(s)

Bemani Peyman | Moazen Setareh | NADIMI ELHAM | NEJATOLLAHI FOROOGH | Issue Writer Certificate

Keywords

ROR1

Phage display

scFV library

Cancer

Abstract

Background: Receptor tyrosine kinase-like orphan receptor 1 (ROR1) is an oncofetal antigen expressed on many types of cancer cells, but not normal adult cells. ROR1 antigen contributes to cancer development and progression by several signaling pathways. ROR1 expression has been associated with tumor growth, survival, and metastasis. In this study specific human recombinant antibodies were selected against ROR1 antigen for their use in cancer immunotherapy. Methods: Phage display technology was used to produce phage antibody from a human scFv library. Phage concentration was determined to confirm the phage rescue process. Panning procedure was performed to isolate specific scFv clones against ROR1 epitope. Phage ELISA was done to evaluate the reactivity of the selected scFvs. Results: Two specific human scFvs with frequencies of 20% and 25% were selected against ROR1 peptide. The antibodies showed specific reaction to the corresponding epitopes in phage ELISA. Conclusions: Cancer targeted therapy using human specific antibodies is a new strategy, which is used in cancer therapy. The selected specific scFvs that target ROR1 epitope are human antibodies that originated from a human library and have the potential to be used in clinic in cancer immunotherapy of ROR1 positive tumors without induction of human anti mouse antibody (HAMA) response.

Multimedia

No record.

Cites

No record.

References

No record.

Cite

APA: Copy

Bemani, Peyman, Moazen, Setareh, NADIMI, ELHAM, & NEJATOLLAHI, FOROOGH. (2022). Development of Human Recombinant Antibodies Against ROR1 Tumor Antigen. REPORTS OF BIOCHEMISTRY AND MOLECULAR BIOLOGY, 11(2), 282-288. SID. https://sid.ir/paper/1131672/en

Vancouver: Copy

Bemani Peyman, Moazen Setareh, NADIMI ELHAM, NEJATOLLAHI FOROOGH. Development of Human Recombinant Antibodies Against ROR1 Tumor Antigen. REPORTS OF BIOCHEMISTRY AND MOLECULAR BIOLOGY[Internet]. 2022;11(2):282-288. Available from: https://sid.ir/paper/1131672/en

IEEE: Copy

Peyman Bemani, Setareh Moazen, ELHAM NADIMI, and FOROOGH NEJATOLLAHI, “Development of Human Recombinant Antibodies Against ROR1 Tumor Antigen,” REPORTS OF BIOCHEMISTRY AND MOLECULAR BIOLOGY, vol. 11, no. 2, pp. 282–288, 2022, [Online]. Available: https://sid.ir/paper/1131672/en

Related Journal Papers

No record.

Related Seminar Papers

No record.

Related Plans

No record.

Recommended Workshops